<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="There are three classes of antiviral drugs approved for the" exact="treatment" post="of influenza: the M2 ion channel inhibitors (amantadine, rimantadine),"/>
 <result pre="There are three classes of antiviral drugs approved for the" exact="treatment" post="of influenza: the M2 ion channel inhibitors (amantadine, rimantadine),"/>
 <result pre="and appears to be persistent over time [3]. During routine" exact="treatment" post="with M2 inhibitors for documented influenza, resistant variants emerge"/>
 <result pre="isolated was low (1–3 %) [29]. Since 2002, though, the" exact="prevalence" post="of resistance to M2 inhibitors among circulating influenza A/H3N2"/>
 <result pre="inhibitors, this class is not recommended for the prevention or" exact="treatment" post="of influenza currently [2]. Detection of Resistance There are"/>
 <result pre="currently [2]. Detection of Resistance There are currently no rapid" exact="tests" post="that can screen for and identify the presence of"/>
 <result pre="Detection of M2 inhibitor resistance has usually relied on virus" exact="isolation" post="from respiratory samples and susceptibility testing of virus in"/>
 <result pre="usually relied on virus isolation from respiratory samples and susceptibility" exact="testing" post="of virus in cell culture. Several assays have been"/>
 <result pre="confirmed by nucleotide sequence analysis of the M2 gene and" exact="detection" post="of the characteristic mutations. Genotypic detection can be accomplished"/>
 <result pre="the M2 gene and detection of the characteristic mutations. Genotypic" exact="detection" post="can be accomplished quickly by the use of PCR"/>
 <result pre="class of drug is not recommended for the prevention or" exact="treatment" post="of influenza [2]. M2 proteins show considerable evolution in"/>
 <result pre="the common emergence of resistant variants as the course of" exact="infection" post="progresses over time. Following treatment, approximately 70–90 % of"/>
 <result pre="A/H1N1-infected children (20 %). Another study employing sensitive molecular cloning" exact="detection" post="methods found mutations conferring resistance in 80 % of"/>
 <result pre="% of 15 hospitalized children during or immediately after amantadine" exact="treatment" post="[41]. Nine (75 %) of 12 children had 2–4"/>
 <result pre="Table 71.2 Recovery of resistant influenza A during M2 inhibitor" exact="treatment" post="Study Seasons Patient group Treatment No. treated No. (%)"/>
 <result pre="[28]. The median time between the first and last virus" exact="isolation" post="was 7 days with range up to 44 days."/>
 <result pre="virus was allowed to transmit through three more sets of" exact="contact" post="birds in the absence of selective drug pressure. Resistant"/>
 <result pre="pressure. Resistant virus was detected from the final set of" exact="contact" post="birds in three of four experiments over four cumulative"/>
 <result pre="household contacts, when ill index cases are not given concurrent" exact="treatment" post="(Table 71.3). In contrast, two studies have found no"/>
 <result pre="rimantadine for postexposure prophylaxis, when the ill index cases received" exact="treatment" post="with the same drug, and one of these documented"/>
 <result pre="and one of these documented failures of prophylaxis due to" exact="infection" post="by drug-resistant variants, most likely transmitted from the treated"/>
 <result pre="the strategy of using M2 inhibitors for both index case" exact="treatment" post="and postexposure prophylaxis in households should be avoided. Table"/>
 <result pre="outbreak [40, 60]. Such findings emphasize the importance of proper" exact="isolation" post="of treated persons and of using NA inhibitors for"/>
 <result pre="isolation of treated persons and of using NA inhibitors for" exact="treatment" post="of ill persons. Pathogenicity M2 inhibitor-resistant influenza A viruses"/>
 <result pre="loss of antiviral effectiveness in vivo. Although severe and progressive" exact="infection" post="with resistant virus has been noted in immunocompromised and"/>
 <result pre="inhibitor-resistant viruses and are appropriate choices for both prophylaxis and" exact="treatment" post="of suspected M2 inhibitor-resistant infections. Clinical studies suggest that"/>
 <result pre="is proven or highly probable [58, 62, 63]. In vitro" exact="testing" post="suggests that the synthetic nucleosides ribavirin and favipiravir are"/>
 <result pre="had a trend to less cough and fewer patients with" exact="detection" post="of M2 inhibitor resistance mutations over the course of"/>
 <result pre="oseltamivir-resistant viruses (n = 44) did not benefit from oseltamivir" exact="treatment" post="(n = 43; P = 0.5) [91]. Similar finding"/>
 <result pre="assay, numerous genotypic PCR-based resistance assays have been developed for" exact="detection" post="of previously identified antiviral resistance mutations in NA [107–110]."/>
 <result pre="rapid and easy to perform, and they allow minor variant" exact="detection" post="(~1–5 % of the quasispecies) with no requirement of"/>
 <result pre="with oseltamivir as outpatients indicated that the frequency of resistance" exact="detection" post="is about 0.4 % in adults and about 4.5"/>
 <result pre="71.6 Frequency of resistance emergence to oseltamivir or zanamivir during" exact="treatment" post="Drug/study Population Assay Virus type No. isolates tested No."/>
 <result pre="antiviral resistance in immunocompromised patients (n = 24); a resistance" exact="prevalence" post="of 17 % (4/24) was reported [158]. In all"/>
 <result pre="the moderate effectiveness of current antivirals, and the relatively high" exact="prevalence" post="of resistance in immunocompromised patient, better treatment strategies are"/>
 <result pre="the relatively high prevalence of resistance in immunocompromised patient, better" exact="treatment" post="strategies are clearly needed for these patients. Pathogenicity and"/>
 <result pre="donor ferret, but once infected, they transmitted the virus to" exact="contact" post="animals with a delay of 1–3 days compared to"/>
 <result pre="Given these findings, most experts recommend using zanamivir for the" exact="treatment" post="of patients who develop resistance or virologic failure to"/>
 <result pre="development [187]. These may provide NA inhibitor prevention and perhaps" exact="treatment" post="alternatives in the future. Ribavirin would also be expected"/>
 <result pre="more effective than ribavirin alone against a lethal influenza A(H1N1)" exact="infection" post="but superior to single agents against influenza B [189]."/>
 <result pre="studied in vitro, in vivo, and in humans with influenza" exact="infection" post="[65, 66, 190]. Given the promise of this combination,"/>
 <result pre="the safety and clinical efficacy of this combination for the" exact="treatment" post="of influenza. Combination therapy has been demonstrated to reduce"/>
 <result pre="given host. Such data can inform the optimal timing of" exact="screening" post="and intervention. Specific risk factors beyond generic concepts, such"/>
 <result pre="M2 inhibitors should not be utilized for the prevention or" exact="treatment" post="of influenza, while any of the neuraminidase inhibitors should"/>
 <result pre="convalescent plasma need to be studied further to optimize the" exact="treatment" post="of patients, particularly with novel or highly resistant viruses"/>
 <result pre="Med Lett Drugs Ther. 2014;56(1457):121–3. 2.FioreAEet al.Antiviral agents for the" exact="treatment" post="and chemoprophylaxis of influenza—recommendations of the Advisory Committee on"/>
 <result pre="Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory" exact="testing" post="methods. Antivir Ther. 2012;17(1 Pt B):159–73. 6.GovorkovaEAet al.Comparison of"/>
 <result pre="influenza resistance information studyJ Infect Dis201621321839010.1093/infdis/jiv37526160744 10.GooskensJet al.Prolonged influenza virus" exact="infection" post="during lymphocytopenia and frequent detection of drug-resistant virusesJ Infect"/>
 <result pre="Dis201621321839010.1093/infdis/jiv37526160744 10.GooskensJet al.Prolonged influenza virus infection during lymphocytopenia and frequent" exact="detection" post="of drug-resistant virusesJ Infect Dis20091991014354110.1086/59868419392620 11.GooskensJet al.Morbidity and mortality"/>
 <result pre="Wilkins134465 18.BelsheRBet al.Genetic basis of resistance to rimantadine emerging during" exact="treatment" post="of influenza virus infectionJ Virol19886251508123282079 19.HayAJRichmanDDAmantadine and rimantadine—mechanismsAntiviral drug"/>
 <result pre="in ferretsJ Infect Dis199116459697210.1093/infdis/164.5.9691940477 23.HallCBet al.Children with influenza A infection:" exact="treatment" post="with rimantadinePediatrics1987802275823302925 24.BelsheRBet al.Resistance of influenza A virus to"/>
 <result pre="Organization Consultation on Human Influenza, A.H. Avian influenza A (H5N1)" exact="infection" post="in humans. N Engl J Med. 2005;353(13):1374–85. 33.GovorkovaEAet al.Antiviral"/>
 <result pre="influenza A (H7N9) virus infectionN Engl J Med20133682422778510.1056/NEJMoa130558423697469 50.GaoRet al.Human" exact="infection" post="with a novel avian-origin influenza A (H7N9) virusN Engl"/>
 <result pre="al.Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients:" exact="detection" post="by polymerase chain reaction-restriction analysisJ Infect Dis199517251352510.1093/infdis/172.5.13527594676 56.BoivinGGoyetteNBernatchezHProlonged excretion"/>
 <result pre="to the neuraminidase inhibitorsBMC Infect Dis20111113410.1186/1471-2334-11-13421592407 73.McKimm-BreschkinJLNeuraminidase inhibitors for the" exact="treatment" post="and prevention of influenzaExpert Opin Pharmacother2002321031210.1517/14656566.3.2.10311829724 74.van der VriesEet"/>
 <result pre="Pharmacother20151612188990010.1517/14656566.2015.106633626153242 86.WatanabeAet al.Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for" exact="treatment" post="of influenza: a double-blind, randomized, noninferiority clinical trialClin Infect"/>
 <result pre="Dis2010511011677510.1086/65680220936975 87.SugayaNOhashiYLong-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as" exact="treatment" post="for children with influenza virus infectionAntimicrob Agents Chemother201054625758210.1128/AAC.01755-0920368393 88.BarnettJMet"/>
 <result pre="Antimicrob Chemother.2000441788710.1128/AAC.44.1.78-87.2000 89.KawaiNet al.Clinical effectiveness of oseltamivir and zanamivir for" exact="treatment" post="of influenza A virus subtype H1N1 with the H274Y"/>
 <result pre="influenza A(H1N1) virus with H274Y neuraminidase mutationJ Infect20095932071210.1016/j.jinf.2009.07.00219619898 91.DharanNJet al.Antiviral" exact="treatment" post="of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal Influenza A"/>
 <result pre="of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal Influenza A (H1N1)" exact="infection" post="during the 2007–2008 influenza season in the United StatesClin"/>
 <result pre="expression of an alpha2,6-linked sialic acid on MDCK cells improves" exact="isolation" post="of human influenza viruses and evaluation of their sensitivity"/>
 <result pre="Dis2013569119720510.1093/cid/cis122023307766 104.HurtACOkomo-AdhiamboMGubarevaLVThe fluorescence neuraminidase inhibition assay: a functional method for" exact="detection" post="of influenza virus resistance to the neuraminidase inhibitorsMethods Mol"/>
 <result pre="Res2015117273810.1016/j.antiviral.2015.02.00325721488 107.van der VriesEet al.Molecular assays for quantitative and qualitative" exact="detection" post="of influenza virus and oseltamivir resistance mutationsJ Mol Diagn20131533475410.1016/j.jmoldx.2012.11.00723597879"/>
 <result pre="inhibitors in seasonal influenza A virusesAntiviral Res2009811162410.1016/j.antiviral.2008.08.00818835410 109.ChutinimitkulSet al.H5N1 Oseltamivir-resistance" exact="detection" post="by real-time PCR using two high sensitivity labeled TaqMan"/>
 <result pre="110.TamuraDet al.Application of a seven-target pyrosequencing assay to improve the" exact="detection" post="of neuraminidase inhibitor-resistant Influenza A(H3N2) virusesAntimicrob Agents Chemother20155942374910.1128/AAC.04939-1425645846 111.RussellRJet"/>
 <result pre="carrying a dual H275Y/I223R mutation from a child after prolonged" exact="treatment" post="with oseltamivirClin Infect Dis2010518983410.1086/65643920858074 117.van der VriesEStelmaFFBoucherCAEmergence of a"/>
 <result pre="to the neuraminidase inhibitors and adamantanesAntiviral Res20077332283110.1016/j.antiviral.2006.10.00417112602 130.LeQMet al.Avian flu:" exact="isolation" post="of drug-resistant H5N1 virusNature20054377062110810.1038/4371108a16228009 131.BeigelJHet al.Avian influenza A (H5N1)"/>
 <result pre="isolation of drug-resistant H5N1 virusNature20054377062110810.1038/4371108a16228009 131.BeigelJHet al.Avian influenza A (H5N1)" exact="infection" post="in humansN Engl J Med20053531313748510.1056/NEJMra05221116192482 132.de JongMDet al.Oseltamivir resistance"/>
 <result pre="in humansN Engl J Med20053531313748510.1056/NEJMra05221116192482 132.de JongMDet al.Oseltamivir resistance during" exact="treatment" post="of influenza A (H5N1) infectionN Engl J Med20053532526677210.1056/NEJMoa05451216371632 133.de"/>
 <result pre="in immunocompromised patients and ferretsPLoS Pathog201395e100334310.1371/journal.ppat.100334323717200 152.BoudreaultAAet al.Impact of corticosteroid" exact="treatment" post="and antiviral therapy on clinical outcomes in hematopoietic cell"/>
 <result pre="with influenza virusBiol Blood Marrow Transplant20111779798610.1016/j.bbmt.2010.09.01420870025 153.IsonMGet al.End points for" exact="testing" post="influenza antiviral treatments for patients at high risk of"/>
 <result pre="virus infection. N Engl J Med. 2010;362(18):1708–19. 156.IsonMGInfluenza prevention and" exact="treatment" post="in transplant recipients and immunocompromised hostsInfluenza Other Respir Viruses20137Suppl"/>
 <result pre="with death or hospitalization due to pandemic 2009 influenza A(H1N1)" exact="infection" post="in CaliforniaJAMA200930217189690210.1001/jama.2009.158319887665 163.IvesJAet al.The H274Y mutation in the influenza"/>
 <result pre="in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate" exact="treatment" post="leave virus severely compromised both in vitro and in"/>
 <result pre="and transmissibilityAntimicrob Agents Chemother2005491040758410.1128/AAC.49.10.4075-4084.200516189083 175.Abed Y et al. Parenteral peramivir" exact="treatment" post="for Oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses. J"/>
 <result pre="al.The use of zanamivir to treat influenza A and B" exact="infection" post="after allogeneic stem cell transplantationBone Marrow Transplant2002292113510.1038/sj.bmt.170334311850704 182.PetersenEet al.Failure"/>
 <result pre="182.PetersenEet al.Failure of combination oral oseltamivir and inhaled zanamivir antiviral" exact="treatment" post="in ventilator- and ECMO-treated critically ill patients with pandemic"/>
 <result pre="al.Evaluation of the antiviral response to zanamivir administered intravenously for" exact="treatment" post="of critically ill patients with pandemic influenza A (H1N1)"/>
 <result pre="antivirals, biotherapeutics and combinationsInfluenza Other Respir Viruses20137Suppl 1637510.1111/irv.1204523279899 188.SmeeDFet al.Combination" exact="treatment" post="of influenza A virus infections in cell culture and"/>
 <result pre="of influenza in households: a prospective, randomized comparison of oseltamivir" exact="treatment" post="with or without postexposure prophylaxisJ Infect Dis20041893440910.1086/38112814745701 215.McKimm-BreschkinJet al.Neuraminidase"/>
 <result pre="Wkly Epidemiol Rec, 2007. 82(17): p. 149-50. 223.WhitleyRJet al.Oral oseltamivir" exact="treatment" post="of influenza in childrenPediatr Infect Dis J20012021273310.1097/00006454-200102000-0000211224828 224.WardPet al.Oseltamivir"/>
 <result pre="pandemicJ Antimicrob Chemother200555Suppl 1i52110.1093/jac/dki01815709056 225.StephensonIet al.Neuraminidase inhibitor resistance after oseltamivir" exact="treatment" post="of acute influenza A and B in childrenClin Infect"/>
</results>
